Objective: To determine the direct treatment cost of unstable angina (UA) withlow molecular weight heparin (LMWH) in conservative management. Study design: Prospectivestudy. Settings: Government cardiovascular hospital and private tertiary care hospital, Karachi.Study period: One year. Method: All 487 patients with either sex having cardiac history ofischemic heart disease, presenting chest pain diagnosed to have unstable angina admitted inhospital for 2-8 days were recruited and entered in study. The current prospective study wasdesigned to analyze the direct treatment cost of UA with LMWH. Data was collected throughproforma and results were analyzed by SPSS version 20. Results: Results were represented interms of percentages, frequencies and means of cost contribution of LMWH. All costs valuesconverted from Pakistani currency (PKR) into US dollars ($) as per exchange rate of 2014. Lessnumber of prescriptions found for fondaparinux (24.85%) than enoxaparin (70%). The estimatedmean of drug cost particularly observed in three treatment groups of patients who receivedenoxaparin, fondaparinux and dalteparin was $36, $ 15 and $ 47 correspondingly. Moreover,4 days total direct cost of enoxaparin and fondaparinux was $191, $ 84 and 6 days treatmentcosts $ 149 with dalteparin to treat a single case of UA. It has been found that fondaparinuxsignificantly lowers the cost of care in comparison to enoxaparin and dalteparin. Conclusion:Current analysis concluded that in the treatment of unstable angina, fondaparinux found to bea dominant strategy that simultaneously lowers the cost of care in conservative management.
UNSTABLE ANGINA DIRECT TREATMENT COST OF UNSTABLE ANGINA WITH LOW MOLECULAR WEIGHT HEPARIN IN CONSERVATIVE MANAGEMENT
